Metastatic Prostatic Adenocarcinoma With Paneth Cell–Like Neuroendocrine Differentiation
A patient in his late 60s with a prior history of widely metastatic prostatic adenocarcinoma was treated with androgen deprivation therapy and docetaxel chemotherapy. On follow-up, serum prostate-specific antigen (PSA) levels were undetectable. However, prostate-specific membrane antigen positron emission tomography imaging was suggestive of pelvic lymph node involvement.